GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

GLP-1s like Ozempic and Wegovy are expensive, with a month’s supply of Ozempic costing around $1,000 without insurance, on average ... the soaring demand for these weight loss drugs, it’s now a ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown ... the high-dose group achieved an average weight loss of 20.7%, compared to 17.5% with the ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Zepbound® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.i ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...